EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Systematic functional screening of immunoreceptor tyrosine-based inhibitory motif domains identifies potent inhibitory modules for chimeric antigen receptor-T

Ting Yang, Min Gao, Yufang Sun, Zhiwei Li, Zijun Xie, Ming Zou, Mi Deng iD

Antibody Therapeutics · 01.04.2026 · 9 (2) · 150-158

DOI: 10.1093/abt/tbag010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 11.03.2026. Verfasst von Ting Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Basic Medical Sciences, Health Science Center, Peking University, Beijing 100191, China. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, National Center of Technology Innovation for Biopharmaceuticals, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematologic malignancies but remains limited by on-target, off-tumor toxicity and the lack of precise mechanisms to restrain aberrant activation. Inhibitory CARs (iCARs) offer a logic-gated strategy to suppress unwanted immune responses, yet optimization of inhibitory signaling modules has been hindered by an incomplete understanding of immunoreceptor tyrosine-based inhibitory motif (ITIM) diversity.

Methods

We established a systematic screening platform to evaluate ITIM-containing intracellular domains (ICDs) from 35 candidate receptors. Using nuclear factor of activated T cells (NFAT) reporter assays across multiple activation contexts, we quantified the ability of each domain to counteract iimmunoreceptor tyrosine-based activating motif (ITAM)-mediated signaling. Intracellular truncated analyses tested the requirement of intact cytoplasmic motifs, and the most potent ITIMs were incorporated into iCAR architectures to assess their capacity to inhibit CAR-driven effector responses.

Results

We identified 12 ITIM domains that strongly suppressed NFAT signaling across diverse activation states. Their inhibitory activity required intact ITIM motifs. When integrated into iCAR constructs, these domains conferred markedly greater suppression of CAR-induced activation compared with conventional programmed cell death protein 1 (PD-1)-based designs. Among them, the SIGLEC9-derived ITIM exhibited the most potent inhibition, significantly reducing CAR-T effector function and protecting target cells from cytotoxicity in vitro.

Conclusions

We identified distinct intracellular modules that effectively suppress CAR-mediated activation, with the SIGLEC9-derived ITIM exhibiting the strongest inhibition. Leveraging domain-specific inhibitory strength enables precise and modular control of T-cell activation, thereby improving the safety, specificity, and tunability of next-generation cellular immunotherapies.

Schlagwörter

Stichwörter der Autor:innen

CAR-T therapyITIM signalingT-cell activationinhibitory CARon-target off-tumor toxicity

Autor:innen und Institutionen

  • Department of Immunology, School of Basic Medical Sciences, Health Science Center, Peking University, Beijing 100191, China.
  • State Key Laboratory of Molecular Oncology, Frontiers Science Center for Cancer Integrative Omics, Peking University International Cancer Institute, Peking University, Beijing 100191, China.
  • State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
  • Beijing Key Laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing 100142, China.

ORCID-Profile: Mi Deng

Förderung

  • National Key Research and Development Program of China
  • National Center of Technology Innovation for Biopharmaceuticals
  • National Natural Science Foundation of China

Zitieren

APA

Yang, T., Gao, M., Sun, Y., Li, Z., Xie, Z., Zou, M., & Deng, M. (2026). Systematic functional screening of immunoreceptor tyrosine-based inhibitory motif domains identifies potent inhibitory modules for chimeric antigen receptor-T. Antibody Therapeutics, 9(2), 150-158. https://doi.org/10.1093/abt/tbag010

Vancouver

Yang T, Gao M, Sun Y, Li Z, Xie Z, Zou M, et al. Systematic functional screening of immunoreceptor tyrosine-based inhibitory motif domains identifies potent inhibitory modules for chimeric antigen receptor-T. Antibody Therapeutics. 2026;9(2):150-158. doi:10.1093/abt/tbag010

BibTeX
@article{Yang2026,
  author = {Yang, Ting and Gao, Min and Sun, Yufang and Li, Zhiwei and Xie, Zijun and Zou, Ming and Deng, Mi},
  title = {Systematic functional screening of immunoreceptor tyrosine-based inhibitory motif domains identifies potent inhibitory modules for chimeric antigen receptor-T},
  journal = {Antibody Therapeutics},
  year = {2026},
  volume = {9},
  number = {2},
  pages = {150--158},
  doi = {10.1093/abt/tbag010}
}
Kostenlos starten →